New Members Have Joined HD-PLC Alliance to Accelerate the HD-PLC Advancement Towards a Global Power Line Communication Standard
3.8.2021 16:00:00 EEST | Business Wire | Press release
HD-PLC Alliance (*1), Fukuoka, Japan (Alliance) announced that 4 newcomers has joined the alliance this year. The member list on Alliance website was updated as follows;
MicroChip Technology as Supporter since July, is a leading provider of smart, connected and secure embedded control solutions. Its easy-to-use development tools and comprehensive product portfolio enable customers to create optimal designs which reduce risk while lowering total system cost and time to market. The company’s solutions serve more than 120,000 customers across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. Microchip is headquartered in Chandler, Arizona.
LVX Global, as Supporter since May, is an international technology solutions business that identifies, designs, delivers and manages high value, scalable, replicable social outcomes at the intersection of technology, engineering, and human behavioural science.
Helvetia, as Standard since May, is a Japanese company. Based on long-time accumulated, experienced knowledge of the industrial field that requires reliability, Helvetia supports enthusiastically to solve customers’ problems of hardware and software design.
And Shanghai Clouder Semiconductor, as Supporter since April, founded in July 2012, is a fabless design house. The company’s main product CR600 uses HD-PLC Inside Plus technology. CR600 application field is mainly two-wire door-phone System.
Since its establishment in 2007, the Alliance has carried out global activities in Europe, U.S.A, Asia to expand and disseminate HD-PLC (*2) and to ensure interoperability. As a result, the global IEEE Standard 1901 (*3) was approved in 2010, adopting HD-PLC as a core technology. "The IEEE 1901 standard is the FIRST standard that converted scattered initiatives into a profitable industry offering assurance of interoperability to users” said Jean-Philippe Faure, IEEE 1901 Working Group Chair. IEEE 1901 has updated as “IEEE 1901 std-2020” early this year to move forward to the 2nd decade.
Comments from these members;
“Microchip is delighted to join the HD-PLC Alliance and extend our product offering with innovative, open-standard and scalable technology solutions. As a leading supplier of total system solutions for smart, connected and secure technology, we look forward to the HD-PLC as a terrific addition to our offering of wired solutions, particularly in the areas of Internet of Things (IoT) and smart energy applications," said Andres Munoz, Marketing Manager, Smart Energy Communications at MicroChip.
“LVX Global is excited to join the HD-PLC Alliance, our participation is part of our belief in building an international global power line communication standard, and is core to having open and reliable communications as well as sustainable systems for the management of smart cities“ said Matthias Lürkens, GM Connectivity & Standardization for LVX Global.
“Helvetia is excited to join the HD-PLC Alliance. Our participation aims to make smart city management a sustainable system using HD-PLC.” said Katsushi Mori, CEO of Helvetia.
“Panasonic's HD-PLC technology provides a cost-effective, safe and reliable simple way for the two-wire door-phone system. We are very happy to be able to introduce HD-PLC Inside Plus technology into the Clouder’s CR600 chip to help customers achieve better efficiency and stability in use. It is a great honor to join the HD-PLC alliance, wish the alliance better and better.” said Lee Jichuan, CEO of Shanghai Clouder Semiconductor.
The Alliance held HD-PLC global web seminars or “Webinars” jointly with IEEE SA in March and June, and explores to organize next Webinar this fall.
The Alliance welcomes other new member to together expand the use of HD-PLC across various use cases in countries around the world.
Note:
*1: The unincorporated association founded by Panasonic Corporation in 2017, which aims to expand and increase the use of HD-PLC and ensure interoperability between equipment with built-in HD-PLC.
*2: HD-PLC™ or HD-PLC™ mark is a registered trademark or trademark of Panasonic Corporation in Japan and in other countries.
*3: IEEE: Institute of Electrical and Electronics Engineers, U.S.A. The global standard on high-speed Power Line Communication that adopted HD-PLC as core technology in 2010. The latest revision, IEEE 1901 std-2020, has been published in January 2021.
https://standards.ieee.org/standard/1901-2020.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005413/en/
Contact information
HD-PLC Alliance
Ryoji Kido,
E-mail: info@hd-plc.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
